Eidos Therapeutics Inc. (NASDAQ:EIDX) went up by 40.33% from its latest closing price compared to the recent 1-year high of $66.56. The company’s stock price has collected 15.20% of gains in the last five trading sessions. Press Release reported 1 hour ago that (EIDX) Alert: Johnson Fistel Investigates Proposed Sale of Eidos Therapeutics; Are Shareholders Getting a Fair Deal?
Is It Worth Investing in Eidos Therapeutics Inc. (NASDAQ :EIDX) Right Now?
Opinions of the stock are interesting as 5 analysts out of 9 who provided ratings for Eidos Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 1 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $58.33, which is -$13.48 below the current price. EIDX currently public float of 12.46M and currently shorts hold a 15.14% ratio of that float. Today, the average trading volume of EIDX was 65.90K shares.
EIDX’s Market Performance
EIDX stocks went up by 15.20% for the week, with a monthly jump of 26.51% and a quarterly performance of 6.18%, while its annual performance rate touched 34.09%. The volatility ratio for the week stands at 7.26% while the volatility levels for the past 30 days are set at 6.31% for Eidos Therapeutics Inc.. The simple moving average for the period of the last 20 days is 52.55% for EIDX stocks with a simple moving average of 51.63% for the last 200 days.
Analysts’ Opinion of EIDX
Citigroup, on the other hand, stated in their research note that they expect to see EIDX reach a price target of $80. The rating they have provided for EIDX stocks is “Buy” according to the report published on September 08th, 2020.
JP Morgan gave a rating of “Neutral” to EIDX, setting the target price at $50 in the report published on May 14th of the current year.
EIDX Trading at 64.84% from the 50-Day Moving Average
After a stumble in the market that brought EIDX to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 9.47% of gains for the given period.
Volatility was left at 6.31%, however, over the last 30 days, the volatility rate increased by 7.26%, as shares surge +75.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +63.80% upper at present.
During the last 5 trading sessions, EIDX rose by +42.72%, which changed the moving average for the period of 200-days by +16.96% in comparison to the 20-day moving average, which settled at $49.31. In addition, Eidos Therapeutics Inc. saw -9.53% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at EIDX starting from Sinha Uma, who sale 4,831 shares at the price of $52.35 back on Oct 01. After this action, Sinha Uma now owns 326,525 shares of Eidos Therapeutics Inc., valued at $252,923 using the latest closing price.
Sinha Uma, the Chief Scientific Officer of Eidos Therapeutics Inc., sale 169 shares at $52.03 during a trade that took place back on Sep 30, which means that Sinha Uma is holding 331,356 shares at $8,794 based on the most recent closing price.
Stock Fundamentals for EIDX
Current profitability levels for the company are sitting at:
- -151.55 for the present operating margin
- +90.35 for the gross margin
The net margin for Eidos Therapeutics Inc. stands at -141.75. The total capital return value is set at -23.27, while invested capital returns managed to touch -21.80. Equity return is now at value -38.60, with -32.80 for asset returns.
Based on Eidos Therapeutics Inc. (EIDX), the company’s capital structure generated 12.40 points at debt to equity in total, while total debt to capital is 11.03. Total debt to assets is 10.43, with long-term debt to equity ratio resting at 12.08. Finally, the long-term debt to capital ratio is 10.74.
When we switch over and look at the enterrpise to sales, we see a ratio of 72.38, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 448.59 and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.78.